FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891608900> ?p ?o ?g. }

• W2891608900 endingPage "219" @default.
• W2891608900 startingPage "210" @default.
• W2891608900 abstract "A therapeutic vaccine for human Chagas disease (American trypanosomiasis caused by Trypanosoma cruzi) is under development based on the success of vaccinating mice with DNA constructs expressing the antigens Tc24 and Tc-TSA-1. However, because DNA and nucleic acid vaccines produce less than optimal responses in humans, our strategy relies on administering a recombinant protein-based vaccine, together with adjuvants that promote Th1-type immunity. Here we describe a process for the purification and refolding of recombinant TSA-1 expressed in Escherichia coli. The overall yield (20–25%) and endotoxin level of the purified recombinant TSA-1 (rTSA-1) is suitable for pilot scale production of the antigen for use in phase 1 clinical trials. Mice infected with T. cruzi were treated with rTSA-1, either alone or with Toll-like receptor 4 (TLR-4) agonist adjuvants including monophosphoryl lipid A (MPLA), glucopyranosyl lipid A (GLA, IDRI), and E6020 (EISEI, Inc). TSA-1 with the TLR-4 agonists was effective at reducing parasitemia relative to rTSA-1 alone, although it was difficult to discern a therapeutic effect compared to treatment with TLR-4 agonists alone. However, rTSA-1 with a 10 ug dose of MPLA optimized reductions in cardiac tissue inflammation, which were significantly reduced compared to MPLA alone. It also elicited the lowest parasite burden and the highest levels of TSA-1-specific IFN-gamma levels and IFN-gamma/IL-4 ratios. These results warrant the further evaluation of rTSA-1 in combination with rTc24 in order to maximize the therapeutic effect of vaccine-linked chemotherapy in both mice and non-human primates before advancing to clinical development." @default.
• W2891608900 created "2018-09-27" @default.
• W2891608900 creator A5012451179 @default.
• W2891608900 creator A5015344901 @default.
• W2891608900 creator A5020411177 @default.
• W2891608900 creator A5026151493 @default.
• W2891608900 creator A5028923514 @default.
• W2891608900 creator A5029943451 @default.
• W2891608900 creator A5030633284 @default.
• W2891608900 creator A5039551236 @default.
• W2891608900 creator A5051342927 @default.
• W2891608900 creator A5053107564 @default.
• W2891608900 creator A5072496895 @default.
• W2891608900 creator A5076951981 @default.
• W2891608900 creator A5087704375 @default.
• W2891608900 date "2018-09-21" @default.
• W2891608900 modified "2023-10-18" @default.
• W2891608900 title "Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of <i>Trypanosoma cruzi</i> infection in mice" @default.
• W2891608900 cites W1512137623 @default.
• W2891608900 cites W1574069111 @default.
• W2891608900 cites W1660215706 @default.
• W2891608900 cites W1916066365 @default.
• W2891608900 cites W1972253258 @default.
• W2891608900 cites W1972747356 @default.
• W2891608900 cites W1976358253 @default.
• W2891608900 cites W1986574729 @default.
• W2891608900 cites W1988310198 @default.
• W2891608900 cites W1996985885 @default.
• W2891608900 cites W2003500126 @default.
• W2891608900 cites W2005580809 @default.
• W2891608900 cites W2019694283 @default.
• W2891608900 cites W2045406234 @default.
• W2891608900 cites W2055623470 @default.
• W2891608900 cites W2072914850 @default.
• W2891608900 cites W2099471639 @default.
• W2891608900 cites W2100170718 @default.
• W2891608900 cites W2107474168 @default.
• W2891608900 cites W2111760376 @default.
• W2891608900 cites W2128897591 @default.
• W2891608900 cites W2132044546 @default.
• W2891608900 cites W2135026276 @default.
• W2891608900 cites W2137586571 @default.
• W2891608900 cites W2143458311 @default.
• W2891608900 cites W2153883117 @default.
• W2891608900 cites W2160661978 @default.
• W2891608900 cites W2161594864 @default.
• W2891608900 cites W2168630917 @default.
• W2891608900 cites W2288026276 @default.
• W2891608900 cites W2318443077 @default.
• W2891608900 cites W2322471444 @default.
• W2891608900 cites W2401894416 @default.
• W2891608900 cites W2477343927 @default.
• W2891608900 cites W2549898682 @default.
• W2891608900 cites W2566193886 @default.
• W2891608900 cites W2589928324 @default.
• W2891608900 cites W2609703381 @default.
• W2891608900 cites W2733394793 @default.
• W2891608900 cites W2751884637 @default.
• W2891608900 cites W4299960106 @default.
• W2891608900 cites W4313342408 @default.
• W2891608900 cites W888308155 @default.
• W2891608900 doi "https://doi.org/10.1080/21645515.2018.1520581" @default.
• W2891608900 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6363145" @default.
• W2891608900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30192702" @default.
• W2891608900 hasPublicationYear "2018" @default.
• W2891608900 type Work @default.
• W2891608900 sameAs 2891608900 @default.
• W2891608900 citedByCount "28" @default.
• W2891608900 countsByYear W28916089002019 @default.
• W2891608900 countsByYear W28916089002020 @default.
• W2891608900 countsByYear W28916089002021 @default.
• W2891608900 countsByYear W28916089002022 @default.
• W2891608900 countsByYear W28916089002023 @default.
• W2891608900 crossrefType "journal-article" @default.
• W2891608900 hasAuthorship W2891608900A5012451179 @default.
• W2891608900 hasAuthorship W2891608900A5015344901 @default.
• W2891608900 hasAuthorship W2891608900A5020411177 @default.
• W2891608900 hasAuthorship W2891608900A5026151493 @default.
• W2891608900 hasAuthorship W2891608900A5028923514 @default.
• W2891608900 hasAuthorship W2891608900A5029943451 @default.
• W2891608900 hasAuthorship W2891608900A5030633284 @default.
• W2891608900 hasAuthorship W2891608900A5039551236 @default.
• W2891608900 hasAuthorship W2891608900A5051342927 @default.
• W2891608900 hasAuthorship W2891608900A5053107564 @default.
• W2891608900 hasAuthorship W2891608900A5072496895 @default.
• W2891608900 hasAuthorship W2891608900A5076951981 @default.
• W2891608900 hasAuthorship W2891608900A5087704375 @default.
• W2891608900 hasBestOaLocation W28916089001 @default.
• W2891608900 hasConcept C104317684 @default.
• W2891608900 hasConcept C112418997 @default.
• W2891608900 hasConcept C136764020 @default.
• W2891608900 hasConcept C147483822 @default.
• W2891608900 hasConcept C159047783 @default.
• W2891608900 hasConcept C167508917 @default.
• W2891608900 hasConcept C203014093 @default.
• W2891608900 hasConcept C2775867548 @default.
• W2891608900 hasConcept C2777625466 @default.
• W2891608900 hasConcept C2778048844 @default.

• next